NCT06894628Recruiting
Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation
Source: ClinicalTrials.gov · Last updated 25 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The study aims to validate the Decipher® genomic test, in which patients with biochemical recurrence after radical prostatectomy are treated with salvage radiotherapy with extreme hypofractionation (5+ Gy/fraction). Validating the Decipher® genomic classifier based on the expression of 22 RNA genes in the prospective study "esSBRT"
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 103 (estimated)
- First submitted
- 18 Mar 2025
- Start date
- 4 Nov 2024
- Primary completion date
- 4 Nov 2027
- Lead sponsor
- Regina Elena Cancer Institute
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT06894628
What you commit to
- Study type: Observational
- Planned participants: 103
- From 4 Nov 2024 to the primary completion date, 4 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- all exclusion criteria adopted for the "esSBRT" study.
Who the study is looking for
- patients enrolled at IRE under the "esSBRT" protocol (meeting the criteria of the same);
- patients who express written informed consent personally or through their legal representative/witness/curator/guardian/support administrator (participation in the ancillary study and data processing)
Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCSS Regina Elena Coordinator of this site? Confirm its status | Roma | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.